Interaction of PF4 (CXCL4) with the vasculature: A role in atherosclerosis and angiogenesis

Thrombosis and Haemostasis

Volumn 104, Issue 5, 2010, Pages 941-948

  Aidoudi Ahmed, Sallouha ^a,b   Bikfalvi, Andreas ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Angiogenesis; Atherosclerosis; CXC chemokine; Integrins; PF4 (CXCL4)

Indexed keywords

ALPHA3 INTEGRIN; ALPHA5 INTEGRIN; ALPHAVBETA5 INTEGRIN; CHEMOKINE RECEPTOR CXCR3; CXCL1 CHEMOKINE; FIBROBLAST GROWTH FACTOR 2; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PROTEOHEPARAN SULFATE; RANTES; THROMBOCYTE FACTOR 4;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ATHEROSCLEROSIS; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CELL SURFACE; ENDOTHELIUM CELL; HUMAN; MACROPHAGE; MONOCYTE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; VASCULARIZATION;

EID: 78149479992     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-03-0193     Document Type: Review

References (86)

1. Levine SP, Wohl H. Human platelet factor 4: Purification and characterization by affinity chromatography. Purification of human platelet factor 4. J Biol Chem 1976; 251: 324-328.
2. Fukami MH, Holmsen H, Kowalska MA, et al. Platelet secretion. In: Hemostasis and Thrombosis. Basis Principles and Clinical Practice. Philadelphia: Lippincott Williams &Wikins 2001: pp. 561-573.
3. Stringer SE, Gallagher JT. Specific binding of the chemokine platelet Factor 4 to heparan sulfate. J Biol Chem 1997; 272: 20508-20514.
4. Handin R, Cohen H. Purification and binding properties of human platelet factor four. J Biol Chem 1976; 251: 4273-4282.
5. Kowalska MA, Rauova L, Poncz M. Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis. Thromb Res 2010; 125: 292-296.
6. Lambert M, Sachais B, Kowalska A. Chemokines and thrombogenicity. Thromb Haemost 2007; 97: 722-729.
7. Maurer AM, Zhou B, Han ZC. Roles of platelet factor 4 in hematopoiesis and angiogenesis. Growth Factors 2006; 24: 242-252.
8. Gewirtz AM, Zhang J, Ratajczak J, et al. Chemokine regulation of human megakaryocytopoiesis. Blood 1995; 86: 2559-2567.
9. Aidoudi S, Guigon M, Lebeurier I, et al. In vivo effect of platelet factor 4 (PF4) and tetrapeptide AcSDKP on haemopoiesis of mice treated with 5-fluorouracil. Br J Haematol 1996; 94: 443-448.
10. von Hundelshausen P, Petersen F, Brandt E. Platelet-derived chemokines in vascular biology. Thromb Haemost 2007; 97: 704-713.
11. Bikfalvi A. Platelet factor 4: an inhibitor of angiogenesis. Semin Thromb Hemost 2004; 30: 379-385.
12. Sachais BS. Elimination of platelet factor 4 (PF4) from platelets reduces atherosclerosis in C57Bl/6 and apoE-/- mice. Thromb Haemost 2007; 98: 1108-1113.
13. Green C, Charles R, Edwards B, et al. Identification and characterization of PF4varl, a human gene variant of platelet factor 4. Mol Cell Biol 1989; 9: 1445-1451.
14. Struyf S, Burdick MD, Proost P, et al. Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis. Circ Res 2004; 95: 855-857.
15. Lasagni L, Grepin R, Mazzinghi B, et al. PF-4/CXCL4 and CXCL4L1 exhibit distinct subcellular localization and a differentially regulated mechanism of secretion. Blood 2007; 109: 4127-4134.
16. Struyf S, Burdick MD, Peeters E, et al. Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. Cancer Res 2007; 67: 5940-5948.
17. Vandercappellen J, Liekens S, Bronckaers A et al. The COOH-terminal peptide of platelet factor-4 variant (CXCL4L1/PF-4var47-70) strongly inhibits angiogenesis and suppresses B16 melanoma growth in vivo. Mol Cancer Res 2010; 8: 322-334.
18. Thaulow E, Erikssen J, Sandvik L, et al. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991; 84: 613-617.
19. Massberg S, Brand K, Gruner S, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002; 196: 887-896.
20. Huo Y, Schober A, Forlow SB, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 9: 61-67.
21. Sevitt S. Platelets and foam cells in the evolution of atherosclerosis. Histological and immunohistological studies of human lesions. Atherosclerosis 1986; 61: 107-115.
22. Pitsilos S, Hunt J, Mohler ER, et al. Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters. Thromb Haemost 2003; 90: 1112-1120.
23. Scheuerer B, Ernst M, Durrbaum-Landmann I, et al. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Blood 2000; 95: 1158-1166.
24. Gleissner CA, Ley K. CXCL4 in atherosclerosis: possible roles in monocyte arrest and macrophage foam cell formation. Thromb Haemost 2007; 98: 917-918.
25. Kasper B, Winoto-Morbach S, Mittelstädt J, et al. CXCL4-induced monocyte survival, cytokine expression, and oxygen radical formation is regulated by sphingosine kinase 1. Eur J Immunol 2010; 40: 1162-1173.
26. Gleissner CA, Shaked I, Erbel C, et al. CXCL4 downregulates the atheroprotective hemoglobin receptor CD163 in human macrophages. Circ Res 2010; 106: 203-211.
27. Luster A, Greenberg S, Leder P. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med 1995; 182: 219-231.
28. Gleissner CA, Shaked I, Little KM, et al. CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages. J Immunol 2010; 184: 4810-4818.
29. Weber C. Platelets and chemokines in atherosclerosis: Partners in Crime. Circ Res 2005; 96: 612-616.
30. von Hundelshausen P, Koenen RR, Sack M, et al. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 2005; 105: 924-930.
31. Koenen RR, Weber C. Therapeutic targeting of chemokine interactions in atherosclerosis. Nat Rev Drug Discov 2010; 9: 141-153.
32. Baltus T, Weber KSC, Johnson Z, et al. Oligomerization of RANTES is required for CCR1-mediated arrest but not CCR5-mediated transmigration of leukocytes on inflamed endothelium. Blood 2003; 102: 1985-1988.
33. Proudfoot AEI, Handel TM, Johnson Z, et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA 2003; 100: 1885-1890.
34. Nesmelova IV, Sham Y, Dudek AZ, et al. Platelet factor 4 and interleukin-8 CXC chemokine heterodimer formation modulates function at the quaternary structural level. J Biol Chem 2005; 280: 4948-4958.
35. Koenen RR, von Hundelshausen P, Nesmelova IV, et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med 2009; 15: 97.
36. Sachais BS, Kuo A, Nassar T, et al. Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic itinerary, resulting in retention of low-density lipoprotein on the cell surface. Blood 2002; 99: 3613-3622.
37. Nassar T, Sachais BS, Akkawi S, et al. H. Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells. J Biol Chem 2003; 278: 6187-6193.
38. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
39. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
40. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-286.
41. Maione TE, Gray GS, Petro J, et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990; 247: 77-79.
42. Davis GE, Senger DR. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 2005; 97: 1093-1107.
43. De S, Razorenova O, Mc Cabe NP, et al. VEGF-integrin interplay controls tumor growth and vascularization. Proc Natl Acad Sci USA 2005; 102: 7589-7594.
44. Hofer E, Schweighofer B. Signal transduction induced in endothelial cells by growth factor receptors involved in angiogenesis. Thromb Haemost 2007; 97: 355-363.
45. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10: 9-22.
46. Jouan V, Canron X, Alemany M, et al. Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action. Blood 1999; 94: 984-993.
47. Hagedorn M, Zilberberg L, Lozano RM, et al. A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2. FASEB J 2001; 15: 550-552.
48. Sharpe RJ, Byers HR, Scott CF, et al. Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst 1990; 82: 848-853.
49. Tanaka T, Manome Y, Wen P, et al. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med 1997; 3: 437-442.
50. Maione TE, Gray GS, Hunt AJ, et al. Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity. Cancer Res 1991; 51: 2077-2083.
51. Bello L, Giussani C, Carrabba G, et al. Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors. Clin Cancer Res 2002; 8: 3539-48.
52. Kolber DL, Knisely TL, Maione TE. Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. J Natl Cancer Inst 1995; 87: 304-309.
53. Zhang C, Thornton MA, Kowalska MA, et al. Localization of distal regulatory domains in the megakaryocyte-specific platelet basic protein/platelet factor 4 gene locus. Blood 2001; 98: 610-617.
54. Lozano RM, Redondo-Horcajo M, Jiminez MA, et al. Solution structure and interaction with basic and acidic fibroblast growth factor of a 3-kDa human platelet factor-4 fragment with antiangiogenic activity. J Biol Chem 2001; 276: 35723-35734.
55. Perollet C, Han ZC, Savona C, et al. Platelet Factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood 1998; 91: 3289-3299. (Pubitemid 28193879)
56. Gengrinovitch S, Greenberg SM, Cohen T, et al. Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms. J Biol Chem 1995; 270: 15059-15065.
57. Sato Y, Abe M, Takaki R. Platelet factor 4 blocks the binding of basic fibroblast growth factor to the receptor and inhibits the spontaneous migration of vascular endothelial cells. Biochem Biophys Res Commun 1990; 172: 595-600. (Pubitemid 20384463)
58. Lasagni L, Francalanci M, Annunziato F, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 2003; 197: 1537-1549.
59. Yu G, Rux AH, Ma P, et al. Endothelial expression of E-selectin is induced by the platelet-specific chemokine platelet factor 4 through LRP in an NF-kappaB-dependent manner. Blood 2005; 105: 3545-3551.
60. Aidoudi S, Bujakowska K, Kieffer N, et al. The CXC-chemokine CXCL4 interacts with integrins implicated in angiogenesis. PLoS One 2008; 3: 2657-2661.
61. Ragona L, Tomaselli S, Quemener C, et al. New insights into the molecular interaction of the C-terminal sequence of CXCL4 with fibroblast growth factor-2. Biochem Biophys Res Commun 2009; 382: 26-29.
62. Sulpice E, Contreres JO, Lacour J, et al. Platelet factor 4 disrupts the intracellular signalling cascade induced by vascular endothelial growth factor by both KDR dependent and independent mechanisms. Eur J Biochem 2004; 271: 3310-3318.
63. Stuckey JA, St Charles R, Edwards BF. A model of the platelet factor 4 complex with heparin. Proteins 1992; 14: 277-287.
64. Mulloy B, Rider CC. Cytokines and proteoglycans: an introductory overview. Biochem Soc Trans 2006; 34: 409-413.
65. Ornitz DM. FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays 2000; 22: 108-112.
66. Petrai I, Rombouts K, Lasagni L, et al. Activation of p38(MAPK) mediates the angiostatic effect of the chemokine receptor CXCR3-B. Int J Biochem Cell Biol 2008; 40: 1764-1774.
67. Lambert MP, Wang Y, Bdeir KH, et al. Platelet factor 4 regulates megakaryopoiesis through low-density lipoprotein receptor-related protein 1 (LRP1) on megakaryocytes. Blood 2009; 14: 2290-2298.
68. Maeshima Y, Sudhakar A, Lively JC, et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002; 295: 140-143.
69. Wickstrom SA, Alitalo K, Keski-Oja J. Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res 2002; 62: 5580-5589.
70. Rehn M, Veikkola T, Kukk-Valdre E, et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci USA 2001; 98: 1024-1029.
71. Sudhakar A, Nyberg P, Keshamouni VG, et al. Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by 11 integrin. J Clin Invest 2005; 115: 2801-2810.
72. Sudhakar A, Sugimoto H, Yang C, et al. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αvβ3 and α5β1 integrins. Proc Natl Acad Sci USA 2003; 100: 4766-4771.
73. Rüegg C, Yilmaz A, Bieler G, et al. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 1998; 4: 408-414.
74. Hansell P, Maione TE, Borgström P. Selective binding of platelet factor 4 to regions of active angiogenesis in vivo. Am J Physiol Heart Circ Physiol 1995; 269: H829-836.
75. Borgström P, Discipio R, Maione TE. Recombinant platelet factor 4, an angiogenic marker for human breast carcinoma. Anticancer Res 1998; 18: 4035-4041.
76. Schwartz MA, Ginsberg MH. Networks and crosstalk: integrin signalling spreads. Nat Cell Biol 2002; 4: E65.
77. Streuli CH, Akhtar N. Signal co-operation between integrins and other receptor systems. Biochem J 2009; 18: 491-506.
78. Mahabeleshwar GH, Feng W, Phillips DR, et al. Integrin signaling is critical for pathological angiogenesis. J Exp Med 2006; 203: 2495-2507.
79. Byzova TV, Goldman CK, Pampori N, et al. A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Mol Cell 2000; 6: 851-860.
80. Koivunen E, Gay DA, Ruoslahti E. Selection of peptides binding to the alpha 5 beta1 integrin from phage display library. J Biol Chem 1993; 268: 20205-20210.
81. Koivunen E, Wang B, Ruoslahti E. Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library. J Cell Biol 1994; 124: 373-380.
82. Chen D, Asahara T, Krasinski K, et al. Antibody blockade of thrombospondin accelerates reendothelialization and reduces neointima formation in balloon-injured Rat Carotid Artery. Circulation 1999; 100: 849-854.
83. Di Stefano R, Felice F, Balbarini A. Angiogenesis as risk factor for plaque vulnerability. Curr Pharm Des 2009; 15: 1095-106.
84. Drinane M, Mollmark J, Zagorchev L, et al. The Antiangiogenic activity of rPAI-123 inhibits vasa vasorum and growth of atherosclerotic plaque. Circ Res 2009; 104: 337-345.
85. Hauer AD, van Puijvelde GH, Peterse N, et al. Vaccination against VEGFR2 attenuates initiation and progression of atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 2050-2057.
86. Westerweel PE, Rabelink TJ, Rookmaaker MB, et al. RANTES is required for ischaemia-induced angiogenesis, which may hamper RANTES-targeted antiatherosclerotic therapy. Thromb Haemost 2008; 99: 794-795.